Editorial

Current Drug Targets

Volumn 12, Issue 12, 2011, Pages 1709-1710

  Ranson, Marie ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE RECEPTOR;

BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL MIGRATION; CELL SURFACE; CELLULAR DISTRIBUTION; CHEMOTAXIS; DISEASE ASSOCIATION; DRUG TARGETING; EDITORIAL; ENDOCYTOSIS; FIBRINOLYSIS; HUMAN; HYPERTENSION; INFECTION; INFLAMMATION; METABOLIC SYNDROME X; METASTASIS; NEOPLASM; NEUROPATHOLOGY; PLASMINOGEN ACTIVATION; PROTEIN DEGRADATION; STROKE; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH; WOUND HEALING; ANIMAL; DRUG ANTAGONISM; METABOLISM; MOLECULARLY TARGETED THERAPY; TRANSLATIONAL RESEARCH;

ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; PLASMINOGEN; PLASMINOGEN ACTIVATORS; PLASMINOGEN INACTIVATORS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TRANSLATIONAL MEDICAL RESEARCH;

EID: 80054066495     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011797635894     Document Type: Editorial

References (13)

1. Lijnen HR. Elements of the fibrinolytic system. Ann N Y Acad Sci 2001; 936: 226-36.
2. Medcalf RL. Plasminogen activation-based thrombolysis for ischaemic stroke: a diversity of targets demands new approaches. Curr Drug Targets 2011; 12: 1772-81.
3. Kriegbaum MC, Persson M, Haldager L, et al. Rational targeting of the urokinase receptor (uPAR): Development of antagonists and non-invasiveimaging probes. Curr Drug Targets 2011; 12: 1711-28.
4. Ngo JCK, Jiang L, Lin Z, et al. Structural basis for therapeutic intervention of uPA/uPAR system. Curr Drug Targets 2011; 12: 1729-43.
5. Carriero MV, Franco P, Votta G, et al. Regulation of cell migration and invasion by specific modules of uPA: mechanistic insights and specific inhibitors. Curr Drug Targets 2011; 12: 1761-71.
6. Lund IK, Illemann M, Thurison T, et al. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy. Curr Drug Targets 2011; 12: 1744-60.
7. Croucher DR, Saunders DN, Lobov S, et al. Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer 2008; 8: 535-45.
8. Strickland DK, Gonias SL, Argraves WS. Diverse roles for the LDL receptor family. Trends Endocrinol Metab 2002; 13: 66-74.
9. Ploplis VA. Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease. Curr Drug Targets 2011; 12: 1782-9.
10. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-312.
11. Cale JM, Lawrence DA. Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent. Curr Drug Targets 2007; 8: 971-81.
12. Croucher DR, Ranson M, Saunders DN. SerpinB2. UCSD-Nature Molecules Page 2010.
13. Tyndall JDA, Kelso MJ, Clingan P, et al. Peptides and small molecules targeting the plasminogen activation system: Towards prophylactic anti-metastasis drugs for breast cancer. Recent Patents Anti-Cancer Drug Discov 2008; 3: 1-13.